Strassberg D S, de Gouveia Brazao C A, Rowland D L, Tan P, Slob A K
University of Utah, Salt Lake City 84112, USA.
J Sex Marital Ther. 1999 Apr-Jun;25(2):89-101. doi: 10.1080/00926239908403982.
Twenty-three premature ejaculators (PEs) and 11 control subjects were administered 25 mg of clomipramine in a double-blind, placebo-controlled, crossover design study. During 2-week trials, subjects took either the drug or the placebo 4 to 6 hours prior to sexual activity. Daily diary data revealed that, for both groups, orgasmic latency was significantly increased when taking the clomipramine. For the PEs, the average increase in orgasmic latency during intercourse was from less than 1 minute to more than 3.5 minutes. Subjects also participated in two laboratory sessions while on the drug and placebo. During these lab sessions they were exposed to erotic videos with and without the addition of vibrotactile stimulation to the penis. Results from the laboratory data support those from the diaries. Specifically, PEs were significantly less likely to reach orgasm during the lab sessions while on the clomipramine than while on the placebo. Further, they reported a significantly greater sense of control over their orgasm while on the drug. The results of this study, along with previous research, strongly support the value of low doses of clomipramine in the treatment of premature ejaculation, specifically when taken on an as-needed basis as little as 4 hours prior to sexual activity. It is important to note, however, that the beneficial effects of the drug were not uniform across clinical subjects. In this study, those PEs with the shortest orgasmic latencies while on the placebo were the least likely to substantially improve while on the drug. Additional research is necessary to determine whether changes in the timing and dosage of the clomipramine administration can extend the benefits of the drug to those with the shortest latencies.
在一项双盲、安慰剂对照、交叉设计研究中，对23名早泄患者（PEs）和11名对照受试者给予25毫克氯米帕明。在为期2周的试验期间，受试者在性活动前4至6小时服用药物或安慰剂。每日日记数据显示，对于两组而言，服用氯米帕明时性高潮潜伏期均显著延长。对于早泄患者，性交时性高潮潜伏期的平均增加幅度从不到1分钟延长至超过3.5分钟。受试者在服用药物和安慰剂期间还参加了两次实验室测试。在这些实验室测试中，他们观看有或没有对阴茎施加振动触觉刺激的色情视频。实验室数据结果支持日记数据结果。具体而言，与服用安慰剂时相比，早泄患者在服用氯米帕明期间的实验室测试中达到性高潮的可能性显著降低。此外，他们报告在服用药物期间对性高潮的控制感明显增强。这项研究的结果以及先前的研究有力地支持了低剂量氯米帕明在治疗早泄方面的价值，特别是在性活动前仅4小时按需服用时。然而，需要注意的是，该药物的有益效果在临床受试者中并不一致。在这项研究中，那些在服用安慰剂时性高潮潜伏期最短的早泄患者在服用药物时最不太可能有显著改善。需要进一步研究以确定氯米帕明给药时间和剂量的变化是否能将该药物的益处扩展到潜伏期最短的患者。
